Patient-specific or office-stock semaglutide preparation dispensed by a 503A licensed compounding pharmacy or 503B FDA-registered outsourcing facility. Not FDA-approved.
Patient-specific or office-stock semaglutide preparation dispensed by a 503A licensed compounding pharmacy or 503B FDA-registered outsourcing facility. Not FDA-approved.
The page lists USP 71 sterility, USP 85 bacterial endotoxin and HPLC potency testing on per-batch certificates of analysis. Note that NexLife’s pages do not state that per-vial certificates of analysis are provided, so ask any provider directly.
A 503A pharmacy is a state-licensed compounding pharmacy working under USP 797 sterile-compounding standards for patient-specific prescriptions. A 503B outsourcing facility is FDA-registered and operates under cGMP manufacturing standards.
NexLife’s plan pages name three 503A pharmacies: Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux’s New Drug Store in Lake Charles, Louisiana. Its medical director is Adam Kennah, M.D.
NexLife lists $139 month to month, or $132, $125 and $119 a month on 3-, 6- and 12-month plans, all charged monthly, the same at every dose with no membership (read October 14, 2026).